Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.
作者： Kishan S. Parikh , Jonathan P. Piccini
DOI: 10.1007/S11897-017-0364-6
关键词:
摘要: We explore the pharmacogenomics of beta-blocker bucindolol by discussing relevant beta-1 adrenergic receptor (ADRB1) polymorphisms and recent studies. Through this, we will understand how may help patients with atrial fibrillation heart failure reduced ejection fraction (AF-HFrEF), which carries poor prognosis. Retrospective study Heart Failure: A Controlled Trial Investigating Outcomes Exercise Training trial revealed interaction between optimal dose ADRB1 Arg389 genotype for HFrEF clinical outcomes. Further, a combinatorial analysis in Beta-Blocker Evaluation Survival showed that Arg389Arg genotype, but not Gly carrier, was associated 40% lower mortality risk bucindolol. Finally, AF-HFrEF subgroup had greater rate reduction suggestion benefit. Therapeutic response to beta-blockers varies mechanism, setting (AF, HFrEF, AF-HFrEF). The ongoing Genotype-Directed Comparative Effectiveness Bucindolol Toprol-XL Prevention Symptomatic Atrial Fibrillation/Atrial Flutter Patients Failure prospectively identifies favorable prevent AF recurrence.
springer.com
sci-hub.se 参考文章(37)
Kevin M. Trulock, Sanjiv M. Narayan, Jonathan P. Piccini, Rhythm Control in Heart Failure Patients With Atrial Fibrillation : Contemporary Challenges Including the Role of Ablation Journal of the American College of Cardiology. ,vol. 64, pp. 710- 721 ,(2014) , 10.1016/J.JACC.2014.06.1169
Lars G Olsson, Karl Swedberg, Anique Ducharme, Christopher B Granger, Eric L Michelson, John JV McMurray, Margareta Puu, Salim Yusuf, Marc A Pfeffer, CHARM investigators, Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction : Results from the candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM) program Journal of the American College of Cardiology. ,vol. 47, pp. 1997- 2004 ,(2006) , 10.1016/J.JACC.2006.01.060
Rosane Charlab, Lei Zhang, Pharmacogenomics: historical perspective and current status. Methods of Molecular Biology. ,vol. 1015, pp. 3- 22 ,(2013) , 10.1007/978-1-62703-435-7_1
David P. Kao, Gordon Davis, Ryan Aleong, Christopher M. O'Connor, Mona Fiuzat, Peter E. Carson, Inder S. Anand, Jonathan F. Plehn, Stephen S. Gottlieb, Marc A. Silver, JoAnn Lindenfeld, Alan B. Miller, Michel White, Guinevere A. Murphy, Will Sauer, Michael R. Bristow, Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. European Journal of Heart Failure. ,vol. 15, pp. 324- 333 ,(2013) , 10.1093/EURJHF/HFS181
Karl Swedberg, Lars G. Olsson, Andrew Charlesworth, John Cleland, Peter Hanrath, Michel Komajda, Marco Metra, Christian Torp-Pedersen, Philip Poole-Wilson, Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET European Heart Journal. ,vol. 26, pp. 1303- 1308 ,(2005) , 10.1093/EURHEARTJ/EHI166
Emelia J Benjamin, Daniel Levy, Sonya M Vaziri, Ralph B D'Agostino, Albert J Belanger, Philip A Wolf, Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. ,vol. 271, pp. 840- 844 ,(1994) , 10.1001/JAMA.1994.03510350050036
Christopher M O'Connor, Mona Fiuzat, Peter E Carson, Inder S Anand, Jonathan F Plehn, Stephen S Gottlieb, Marc A Silver, JoAnn Lindenfeld, Alan B Miller, Michel White, Ryan Walsh, Penny Nelson, Allen Medway, Gordon Davis, Alastair D Robertson, J David Port, James Carr, Guinevere A Murphy, Laura C Lazzeroni, William T Abraham, Stephen B Liggett, Michael R Bristow, None, Combinatorial Pharmacogenetic Interactions of Bucindolol and β1, α2C Adrenergic Receptor Polymorphisms PLoS ONE. ,vol. 7, pp. e44324- ,(2012) , 10.1371/JOURNAL.PONE.0044324
Jonathan D. Sackner-Bernstein, Rationale for Treatment of Patients With Chronic Heart Failure With Adrenergic Blockade JAMA: The Journal of the American Medical Association. ,vol. 274, pp. 1462- 1467 ,(1995) , 10.1001/JAMA.1995.03530180056031
Kishan S. Parikh, Tariq Ahmad, Mona Fiuzat, Potential Applications of Pharmacogenomics to Heart Failure Therapies Heart Failure Clinics. ,vol. 10, pp. 599- 606 ,(2014) , 10.1016/J.HFC.2014.07.007
Mathew R. Taylor, Albert Y. Sun, Gordon Davis, Mona Fiuzat, Stephen B. Liggett, Michael R. Bristow, Race, common genetic variation, and therapeutic response disparities in heart failure. Jacc-Heart Failure. ,vol. 2, pp. 561- 572 ,(2014) , 10.1016/J.JCHF.2014.06.010